<DOC>
	<DOCNO>NCT00003330</DOCNO>
	<brief_summary>Phase I trial study effectiveness interleukin-12 treating patient advance cancer . Interleukin-12 may kill tumor cell stop blood flow tumor stimulate person 's white blood cell kill cancer cell .</brief_summary>
	<brief_title>Interleukin-12 Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity profile maximum tolerate dose ( MTD ) intravenous interleukin-12 ( IL-12 ) administer biweekly 6-18 week presence absence test dose patient metastatic unresectable malignancy . II . Determine optimal time administration IL-12 test dose , base impact secondary biologic parameter patient . III . Determine antitumor effect IL-12 administer accord schedule , without test dose , patient . IV . Determine effect test dose toxicity profile , MTD , tumor response various biologic phenomenon serum , , possible , tumor liver patient . OUTLINE : This 3-part dose escalation study . In Part A , patient receive intravenous interleukin-12 ( IL-12 ) twice week 6 week . Courses repeat patient achieve complete response disease progression . Dose escalation IL-12 continue cohort 3-6 patient maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity ( DLT ) . In Part B , patient receive single test dose IL-12 administer intravenously 1 , 2 , 3 week interval prior start multidose twice week regimen Part A . Cohorts 4 patient receive IL-12 MTD obtain Part A . In Part C , patient receive IL-12 one dose level MTD obtain Part A use optimal schedule test dose determine Part B . Dose escalation continue cohort 3-6 patient MTD determine . The MTD define dose 2 6 patient experience DLT . Patients may continue receive IL-12 measurable disease disease progression .</detailed_description>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy metastatic unresectable standard curative palliative measure exist longer effective Advanced measurable evaluable disease clearly progressive No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Karnofsky 80100 % Life expectancy : At least 3 month WBC great 4,000/mm3 Platelet count great 100,000/mm3 Bilirubin less 1.5 mg/dL SGOT/SGPT le 2 time normal Creatinine le 1.5 mg/dL Creatinine clearance least 60 mL/min No congestive heart failure No coronary artery disease No serious cardiac arrhythmias No evidence prior myocardial infarction EKG Not pregnant nursing Fertile patient must use effective contraception Not HIV positive No seizure disorder No active infection require antibiotic therapy No significant medical disease malignancy PRIOR CONCURRENT THERAPY : No 2 prior biological response modifier treatment regimen No immunotherapy within past 4 week No prior interleukin12 No 2 prior chemotherapy regimen At least 4 week since chemotherapy recover At least 6 week since nitrosoureas mitomycin recover No concurrent chemotherapy At least 4 week since hormone therapy recover No concurrent hormone therapy No concurrent corticosteroid At least 4 week since radiotherapy recover No concurrent radiotherapy No organ allograft At least 2 week since intravenous antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>